{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:58:43Z","timestamp":1793797123843,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ejpb.2025.114663","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:49:57Z","timestamp":1738828197000},"page":"114663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Repeated sequential administration of pegylated emulsion of SU5416 and liposomal paclitaxel enhances anti-tumor effect in 4T1 breast cancer-bearing mice"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-2813","authenticated-orcid":false,"given":"Masato","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiya","family":"Torii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1307-7122","authenticated-orcid":false,"given":"Ken-ichi","family":"Ogawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0824-8575","authenticated-orcid":false,"given":"Kazutaka","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114663_b0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3892\/ijo.2016.3709","article-title":"Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)","volume":"49","author":"Maj","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejpb.2025.114663_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1026529222845","article-title":"Endothelial cells of tumor vessels: abnormal but not absent","volume":"19","author":"McDonald","year":"2000","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejpb.2025.114663_b0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/jcb.21187","article-title":"Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize","volume":"101","author":"Fukumura","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejpb.2025.114663_b0020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"10.1016\/j.ejpb.2025.114663_b0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2025.114663_b0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejpb.2025.114663_b0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2025.114663_b0040","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2025.114663_b0045","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","article-title":"Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11","volume":"88","author":"Wildiers","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0050","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1158\/0008-5472.CAN-06-1854","article-title":"Mechanism of Reoxygenation after Antiangiogenic Therapy Using SU5416 and Its Importance for Guiding Combined Antitumor Therapy","volume":"66","author":"Ansiaux","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114663_b0055","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114663_b0060","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.11315","article-title":"Phase II study of SU5416\u2013a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor\u2013in patients with refractory myeloproliferative diseases","volume":"97","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0065","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1021\/mp300318q","article-title":"Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416","volume":"9","author":"Yoshizawa","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114663_b0070","article-title":"Vascular normalization with pegylated emulsion of SU5416 enhances anti-tumor effect of liposomal paclitaxel in 4T1 breast cancer-bearing mice: Analysis of intratumoral vessels and microenvironment","volume":"96","author":"Maruyama","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2025.114663_b0075","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","article-title":"What is triple-negative breast cancer?","volume":"44","author":"Irvin","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0080","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.3390\/jcm11206021","article-title":"Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists\u2019 Perspective","volume":"11","author":"Li","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejpb.2025.114663_b0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejpb.2025.114663_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2011.04.008","article-title":"PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy","volume":"412","author":"Yoshizawa","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114663_b0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jconrel.2004.12.018","article-title":"Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor","volume":"103","author":"Lee","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2025.114663_b0100","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/ATVBAHA.107.158014","article-title":"VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation","volume":"28","author":"Vestweber","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejpb.2025.114663_b0105","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/0008-5472.CAN-13-1989","article-title":"Benefits of vascular normalization are dose and time dependent\u2013letter","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114663_b0110","first-page":"7075","article-title":"Hypoxia-inducible expression of tumor-associated carbonic anhydrases - PubMed","volume":"60","author":"Wykoff","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114663_b0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","article-title":"Activated fibroblasts in cancer: Perspectives and challenges","volume":"41","author":"Caligiuri","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejpb.2025.114663_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13061399","article-title":"The Role of Cancer-Associated Fibroblasts in Tumor Progression","volume":"13","author":"Joshi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2025.114663_b0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0130","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2025.114663_b0135","first-page":"482","article-title":"Cancer associated fibroblasts: the dark side of the coin","volume":"1","author":"Cirri","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejpb.2025.114663_b0140","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.3390\/cancers13174442","article-title":"The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options","volume":"13","author":"Ferrara","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2025.114663_b0145","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1021\/acs.molpharmaceut.0c00014","article-title":"Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration","volume":"17","author":"Guo","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2025.114663_b0150","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.3390\/cancers14153570","article-title":"Fight the Cancer, Hit the CAF!","volume":"14","author":"Papait","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejpb.2025.114663_b0155","first-page":"10","volume":"7","author":"Petrova","year":"2018","journal-title":"The Hypoxic Tumour Microenvironment. Oncogenesis"},{"key":"10.1016\/j.ejpb.2025.114663_b0160","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0165","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0170","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/srep02038","article-title":"MiR-21\/Smad 7 signaling determines TGF-\u03b21-induced CAF formation","volume":"3","author":"Li","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejpb.2025.114663_b0175","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10555-012-9415-3","article-title":"Stromal cells in tumor microenvironment and breast cancer","volume":"32","author":"Mao","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejpb.2025.114663_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom10121666","article-title":"Transforming Growth Factor-\u03b2 Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts","volume":"10","author":"Shi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejpb.2025.114663_b0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41389-021-00302-5","article-title":"TGF-\u03b21-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in gastrointestinal stromal tumor","volume":"10","author":"Yoon","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejpb.2025.114663_b0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/pros.10279","article-title":"Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia","volume":"57","author":"Berger","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.ejpb.2025.114663_b0195","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2013a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0200","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejpb.2025.114663_b0205","doi-asserted-by":"crossref","first-page":"249","DOI":"10.14740\/wjon1517","article-title":"Cancer progression is not different in mice of different gender inoculated with cells of the triple-negative 4T1 breast cancer model","volume":"13","author":"Albores-Mendez","year":"2022","journal-title":"World J. Oncol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T16:53:22Z","timestamp":1741280002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"alternative-id":["S0939641125000396"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114663","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeated sequential administration of pegylated emulsion of SU5416 and liposomal paclitaxel enhances anti-tumor effect in 4T1 breast cancer-bearing mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114663"}}